Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Technology Process of Brensocatib

Brensocatib

Base Information
  • Chemical Name:Brensocatib
  • CAS No.:1802148-05-5
  • Molecular Formula:C23H24N4O4
  • Molecular Weight:420.5
  • Hs Code.:
  • European Community (EC) Number:814-271-5
  • UNII:25CG88L0BB
  • Nikkaji Number:J3.556.230C
  • NCI Thesaurus Code:C171778
  • Pharos Ligand ID:1XF6BSHK6PZT
  • Metabolomics Workbench ID:155579
  • ChEMBL ID:CHEMBL3900409
Brensocatib

Synonyms:AZD7986;brensocatib;INS-1007;INS1007;N-(1-cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide

Suppliers and Price of Brensocatib
Supply Marketing:
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
  • AK Scientific
  • Brensocatib
  • 50mg
  • $ 860.00
  • Biosynth Carbosynth
  • Brensocatib
  • 100 mg
  • $ 950.00
  • Biosynth Carbosynth
  • Brensocatib
  • 50 mg
  • $ 600.00
  • Biosynth Carbosynth
  • Brensocatib
  • 10 mg
  • $ 250.00
  • Biosynth Carbosynth
  • Brensocatib
  • 25 mg
  • $ 450.00
  • Biosynth Carbosynth
  • Brensocatib
  • 250 mg
  • $ 1500.00
  • ChemScene
  • Brensocatib 99.66%
  • 50mg
  • $ 2100.00
  • ChemScene
  • Brensocatib 99.66%
  • 100mg
  • $ 2950.00
  • ChemScene
  • Brensocatib 99.66%
  • 25mg
  • $ 1500.00
  • ChemScene
  • Brensocatib 99.66%
  • 5mg
  • $ 450.00
Total 13 raw suppliers
Chemical Property of Brensocatib
Chemical Property:
  • XLogP3:2
  • Hydrogen Bond Donor Count:2
  • Hydrogen Bond Acceptor Count:6
  • Rotatable Bond Count:5
  • Exact Mass:420.17975526
  • Heavy Atom Count:31
  • Complexity:699
Purity/Quality:

99%, *data from raw suppliers

Brensocatib *data from reagent suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:
Useful:
  • Canonical SMILES:CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)CC(C#N)NC(=O)C4CNCCCO4)OC1=O
  • Isomeric SMILES:CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
  • Recent ClinicalTrials:A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
  • Recent EU Clinical Trials:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study
  • Recent NIPH Clinical Trials:A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
  • Uses AZD7986, is a highly potent, reversible, and selective cinical candidate acting as DPP1 Inhibitor, with predicted to have human PK properties suitable for once daily human dosing.
Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1802148-05-5

Total 8 Pictures about this product